Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916453 | 0.90 | ACHE (0.47) | ACHELMNASMN1; SMN2 | |
| SCHEMBL15472422 | 0.88 | ACHE (0.46) | ACHELMNASMN1; SMN2 | |
| SCHEMBL17486506 | 0.86 | ACHE (0.45) | ACHELMNASMN1; SMN2 | |
| SCHEMBL10310617 | 0.86 | ACHE (0.41) | ACHELMNASMN1; SMN2 | |
| SCHEMBL11141024 | 0.86 | ACHE (0.52) | ACHEL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL15474204 | 0.85 | ACHE (0.51) | ACHELMNASMN1; SMN2 | |
| SCHEMBL12382267 | 0.84 | ACHE (0.44) | ACHELMNASMN1; SMN2 | |
| SCHEMBL9494648 | 0.84 | ACHE (0.58) | ACHE | |
| SCHEMBL12419070 | 0.84 | ACHE (0.44) | ACHE | |
| SCHEMBL12038086 | 0.84 | ACHE (0.46) | ACHELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-8586711-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-19 | — | — | US | disclosed |
| US-8143378-B2 | Polymer factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | NEKTAR THERAPEUTICS (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | ACHE 4361/4885MAPT 2053/4885L3MBTL1 3235/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ACHE 4006/4885MAPT 3026/4885L3MBTL1 2678/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ACHE 4136/4885MAPT 2860/4885L3MBTL1 2526/4885 |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | GAA, MAN2B1, GBA1 | ACHE 2348/4885MAPT 805/4885L3MBTL1 628/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | ACHE 4502/4885MAPT 1315/4885L3MBTL1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.